Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-146

Everything looks spot on, although with your first point, affected families and patients have also been reaching for compassionate use.

And also strongly agree that it was a great Q&A, all my concerns were stomped away, especially when they stated the exact reasons for providing which data within the current release, which was purely for FDA notice and box ticking, than also all funding covered, interest from big and small companies, and as you mentioned, going back to MJFF.

Anyways, need to sleep, or i wont be able to switch off.